Downregulation of ubiquitin level via knockdown of polyubiquitin gene Ubb as potential cancer therapeutic intervention

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Oh, Choongseob ^a   Park, Soonyong ^a   Lee, Eun Kyung ^b   Yoo, Yung Joon ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; POLYUBIQUITIN; TUMOR NECROSIS FACTOR ALPHA; UBB PROTEIN, HUMAN; UBIQUITIN;

ANIMAL; APOPTOSIS; ARTICLE; CELL LINE; CELL PROLIFERATION; DISEASE MODEL; DOWN REGULATION; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; MALE; MCF 7 CELL LINE; METABOLISM; MOUSE; NEOPLASM; PROTEIN DEGRADATION; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR VOLUME; UBIQUITINATION;

ANIMALS; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MCF-7 CELLS; MICE; NEOPLASMS; NF-KAPPA B; POLYUBIQUITIN; PROTEOLYSIS; RNA INTERFERENCE; TUMOR BURDEN; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN; UBIQUITINATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902905650     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02623     Document Type: Article

References (44)

1. Hershko, A. & Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem. 67, 425-479 (1998).
2. Pickart, C. M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70, 503-533 (2001).
3. Weissman, A. M. Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell Biol. 2, 169-178 (2001).
4. Kulathu, Y. & Komander, D. Atypical ubiquitylation-the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nat. Rev. Mol. Cell Biol. 13, 508-523 (2012).
5. Husnjak, K. & Dikic, I. Ubiquitin-binding proteins: decoders of ubiquitinmediated cellular functions. Annu. Rev. Biochem. 81, 291-322 (2012).
6. Hicke, L., Schubert, H. L. & Hill, C. P. Ubiquitin-binding domains. Nat. Rev. Mol. Cell Biol. 6, 610-621 (2005).
7. Reyes-Turcu, F. E., Ventii, K. H. &Wilkinson, K. D. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu. Rev. Biochem. 78, 363-397 (2009).
8. Ciechanover, A. & Schwartz, A. L. The ubiquitin system: pathogenesis of human diseases and drug targeting. Biochim. Biophys. Acta 1695, 3-17 (2004).
9. Hoeller, D. & Dikic, I. Targeting the ubiquitin system in cancer therapy. Nature 458, 438-444 (2009).
10. Bedford, L., Lowe, J., Dick, L. R., Mayer, R. J. & Brownell, J. E. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat. Rev. Drug Discov. 10, 29-46 (2011).
11. Yang, Y. et al. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res. 67, 9472-9481 (2007).
12. Verma, R. et al. Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science 306, 117-120 (2004).
13. Fraile, J. M., Quesada, V., Rodriguez, D., Freije, J. M. & Lopez-Otin, C. Deubiquitinases in cancer: new functions and therapeutic options. Oncogene 31, 2373-2388 (2012).
14. Ishibashi, Y. et al. Ubiquitin immunoreactivity in human malignant tumours. Br. J. Cancer 63, 320-322 (1991).
15. Kanayama, H. et al. Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res. 51, 6677-6685 (1991).
16. Ishibashi, Y. et al. Quantitative analysis of free ubiquitin and multi-ubiquitin chain in colorectal cancer. Cancer Lett. 211, 111-117 (2004).
17. Morelva Tde, M. & Antonio, L. B. Immunohistochemical expression of ubiquitin and telomerase in cervical cancer. Virchows Arch. 455, 235-243 (2009).
18. Finch, J. S. et al. Overexpression of three ubiquitin genes in mouse epidermal tumors is associated with enhanced cellular proliferation and stress. Cell Growth Differ. 3, 269-278 (1992).
19. Osada, T. et al. Increased ubiquitin immunoreactivity in hepatocellular carcinomas and precancerous lesions of the liver. J. Hepatol. 26, 1266-1273 (1997).
20. Turner, G. C. & Varshavsky, A. Detecting and measuring cotranslational protein degradation in vivo. Science 289, 2117-2120 (2000).
21. Bhoj, V. G. & Chen, Z. J. Ubiquitylation in innate and adaptive immunity. Nature 458, 430-437 (2009).
22. Luo, J., Solimini, N. L. & Elledge, S. J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823-837 (2009).
23. Neznanov, N., Komarov, A. P., Neznanova, L., Stanhope-Baker, P. & Gudkov, A. V. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget 2, 209-221 (2011).
24. Fornace Jr., A. J., Alamo Jr., I., Hollander, M. C. & Lamoreaux, E. Ubiquitin mRNAis amajor stress-induced transcript in mammalian cells. Nucleic Acids Res. 17, 1215-1230 (1989).
25. Finley, D.,Ozkaynak, E.&Varshavsky, A. The yeast polyubiquitin gene is essential for resistance to high temperatures, starvation, and other stresses. Cell 48, 1035-1046 (1987).
26. Bence, N. F., Sampat, R. M. & Kopito, R. R. Impairment of the ubiquitinproteasome system by protein aggregation. Science 292, 1552-1555 (2001).
27. Mukhopadhyay, D. & Riezman, H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science 315, 201-205 (2007).
28. Karin,M. Nuclear factor-kappaB in cancer development and progression. Nature 441, 431-436 (2006).
29. Nakanishi, C. & Toi, M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 5, 297-309 (2005).
30. Kimura, Y. & Tanaka, K. Regulatory mechanisms involved in the control of ubiquitin homeostasis. J. Biochem. 147, 793-798 (2010).
31. Kitagaki, J. et al. Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53. Oncogene 28, 619-624 (2009).
32. Xu, G.W. et al. The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood 115, 2251-2259 (2010).
33. Ryu, K. Y. et al. The mouse polyubiquitin gene UbC is essential for fetal liver development, cell-cycle progression and stress tolerance. Embo J. 26, 2693-2706 (2007).
34. Ryu, K. Y., Garza, J. C., Lu, X. Y., Barsh, G. S. & Kopito, R. R. Hypothalamic neurodegeneration and adult-onset obesity in mice lacking the Ubb polyubiquitin gene. Proc. Natl. Acad. Sci. U S A 105, 4016-4021 (2008).
35. Ghobrial, I. M., Witzig, T. E. & Adjei, A. A. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 55, 178-194 (2005).
36. Fesik, S. W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 5, 876-885 (2005).
37. Hanahan, D.&Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
38. Lindquist, S. The heat-shock response. Annu. Rev. Biochem. 55, 1151-1191 (1986).
39. Sherman, M. Y. Proteotoxic stress targeted therapy (PSTT). Oncotarget 2, 356-357 (2011).
40. Maloney, A.&Workman, P.HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther. 2, 3-24 (2002).
41. Wojcik, C. et al. Valosin-containing protein (p97) is a regulator of endoplasmic reticulum stress and of the degradation of N-end rule and ubiquitin-fusion degradation pathway substrates inmammalian cells. Mol. Biol. Cell 17, 4606-4618 (2006).
42. Lee, E. K., Park, Y. W., Shin, D. Y.,Mook-Jung, I. & Yoo, Y. J. Cytosolic amyloidbeta peptide 42 escaping from degradation induces cell death. Biochem. Biophys. Res. Commun. 344, 471-477 (2006).
43. Shin, D. Y., Lee, H., Park, E. S. & Yoo, Y. J. Assembly of different length of polyubiquitins on the catalytic cysteine of E2 enzymes without E3 ligase; a novel application of non-reduced/reduced 2-dimensional electrophoresis. FEBS Lett. 585, 3959-3963 (2011).
44. Carmichael, J., DeGraff, W. G., Gazdar, A. F., Minna, J. D. & Mitchell, J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res. 47, 943-946 (1987).